Compare Levi Strauss & Co. (LEVI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Tango Therapeutics Inc. — how do they compare? Levi Strauss & Co. trades at $19.6 (market cap $7.47B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Levi Strauss & Co. is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.29% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 71 Days and Tango Therapeutics Inc. for 0 Days on average.
| LEVI | TNGX | |
|---|---|---|
Market Cap | $7.47B | $3.75B |
Volume | 6,427,839 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $32.90 |
52-Week Low | $17.92 | $7.50 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $9.02B | $2.77B |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.57, up 1.72% with strong fundamentals including a 12.82 P/E ratio and 25.76% ROE. The stock shows bearish technical signals but has consistently beaten earnings expectations for four consecutive quarters. Recent news highlights the company's successful '90s fashion revival and appointment of a new CFO, while analyst consensus remains strongly bullish with a $29 price target representing 48% upside potential.
The investment case balances attractive valuation against technical weakness. Strong profitability metrics and consistent earnings beats support upside, but bearish technical indicators and execution risks in the competitive apparel sector warrant caution. The 78.95% buy rating from analysts suggests significant institutional confidence in Levi's growth trajectory despite near-term market sentiment concerns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
